Sign in

CIK 0000921299

  • Non-accelerated filer
  • Smaller reporting company

KYNTRA BIO, INC.

Sign in to watch
Ticker
KYNB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
770357827
Phone
+1 415-978-1200
Business address
350 BAY STREET, SUITE 100 #6009, SAN FRANCISCO, CA, 94133
Former names
FIBROGEN INC
  1. 4 Open-market sale Director sold 18,000 shares at $35.02 ($630,360)
  2. 4 Shares withheld for taxes SVP, Clinical Dev, Drug Safety gave up 5,221 shares (to pay taxes)
  3. 4 Shares withheld for taxes SVP, Finance and CFO gave up 5,657 shares (to pay taxes)
  4. 4 Shares withheld for taxes SVP, China Operations gave up 5,679 shares (to pay taxes)
  5. 4 Grant or award Chief Commercial Officer acquired 16,500 shares (grant or award)
  6. 4 Grant or award SVP, Clinical Dev, Drug Safety acquired 20,800 shares (grant or award)
  7. 4 Grant or award SVP, Finance and CFO acquired 21,700 shares (grant or award)
  8. 4 Grant or award SVP, China Operations acquired 21,700 shares (grant or award)
  9. 4 Grant or award Chief Executive Officer acquired 82,000 shares (grant or award)
  10. 3/A Insider 3/A
  11. 4 Open-market sale Director sold 6,000 shares at an average $52.40 ($314,383)
  12. 4 Open-market sale Director sold 6,000 shares at $43.38 ($260,280)
  13. 4 Open-market sale Director sold 5,999 shares at $40.04 ($240,200)
  14. 4 Shares withheld for taxes Chief Executive Officer gave up 5,411 shares (to pay taxes)
  15. 4 Exercise or conversion Director acquired 6,000 shares (option exercise)
  16. 4 Open-market sale Director sold 6,001 shares at an average $40.40 ($242,455)
  17. 4 Open-market sale Chief Medical Officer sold 3,350 shares at $41.61 ($139,394)
  18. 4 Open-market sale SVP, Finance and CFO sold 3,068 shares at $43.60 ($133,765)
  19. 4 Shares withheld for taxes Chief Medical Officer gave up 3,292 shares (to pay taxes)
  20. 4 Shares withheld for taxes SVP, Clinical Dev, Drug Safety gave up 2,728 shares (to pay taxes)

Page 11 of 38 · 760 filings